Amgen’s Patent Thicket Strategy Yields Billions in Drug Sales for TNF Inhibitor Enbrel
Amgen has employed a powerful strategy to maintain its monopoly on Enbrel, a drug that targets tumor necrosis factor (TNF) [...]
Merck and Amgen Boldly Test the Limits of Prescription Drug Price Increases
Pharmaceutical companies generally keep drug prices increases around 5% per year. This year, Merck and Amgen tested that unofficial limit. [...]
Will Patient RWD Improve Cardiovascular Disease Outcomes?
Amgen and Datos Health have partnered to explore how RWD (real world data) can improve outcomes for heart disease patients. Using [...]
Amgen Tops Cost Watchdog’s Price Gougers List
In a top 10 ranking of the most egregious price gougers from 2019, Amgen’s Enbrel topped US cost watchdog ICER’s [...]
[Presentation] IMPACCT: Real World Evidence–The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan
[Presentation] IMPACCT: Real World Evidence--The Rile of Real World Evidence (RWE) in a Comprehensive Product Evidence Generation Plan by Cathy [...]
Advertisement
